157 related articles for article (PubMed ID: 37072246)
1. Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment.
Kooti W; Esmaeili HGG; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M
Klin Onkol; 2023; 36(2):124-129. PubMed ID: 37072246
[TBL] [Abstract][Full Text] [Related]
2. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
3. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo.
Al-Shammari AM; Jalill RDA; Hussein MF
Mol Biol Rep; 2020 Mar; 47(3):1691-1702. PubMed ID: 31970625
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.
Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A
Virol J; 2020 May; 17(1):64. PubMed ID: 32370750
[TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
8. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D; Palese P
Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
11. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
12. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
13. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
14. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
[TBL] [Abstract][Full Text] [Related]
15. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
16. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the oncolytic potential of R
Sharma KK; Kalyani IH; Mohapatra J; Patel SD; Patel DR; Vihol PD; Chatterjee A; Patel DR; Vyas B
Arch Virol; 2017 Sep; 162(9):2705-2713. PubMed ID: 28578522
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.
Yurchenko KS; Zhou P; Kovner AV; Zavjalov EL; Shestopalova LV; Shestopalov AM
PLoS One; 2018; 13(4):e0195425. PubMed ID: 29621357
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
[TBL] [Abstract][Full Text] [Related]
20. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J; Hamid A; Yusoff K; Chia SL
Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
